中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Pipeline
Pipeline
Clinical Trials
Partnership
Investors
Financials & Filing
Upcoming Events
Presentations
News
Careers
Investors
Financials & Filing
Upcoming Events
Presentations
2025
2024
2023
2022
2021
2020
2019
2018
2025
2024
2023
2022
2021
2020
2019
2018
Next Day Disclosure Returns - Share Buyback
2024-10-15
Next Day Disclosure Returns - Share Buyback
2024-10-14
Next Day Disclosure Returns - Share Buyback
2024-10-10
Next Day Disclosure Returns - Share Buyback
2024-10-09
Next Day Disclosure Returns - Share Buyback
2024-10-08
Next Day Disclosure Returns - Share Buyback
2024-10-07
Inside Information - Update on Legal Proceedings Involving ASC41 and ASC43F
2024-10-07
Voluntary Announcement - Gannex’s Strategic Partner Sagimet Announces Receipt of FDA Breakthrough Therapy Designation for ASC40 (Denifanstat) for Treatment of Biopsy-Confirmed F2/F3 MASH
2024-10-03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
2024-10-02
Next Day Disclosure Returns - Share Buyback
2024-09-30
«
5
6
7
8
»
浙公网安备 33010802003344号
浙ICP备11050387号-1